DDIT3 and lymphoma: These new insights into the molecular underpinnings of DBCL biology suggest that targeting the FCRL1/BAFF axis may represent a novel therapeutic strategy of personalized approaches to lymphoma treatment, particularly for high-risk patients who exhibit poor responses to conventional R-CHOP therapy.